Moreover, it has been reported that blasts obtained from patients with relapsed FLT3 ITD-positive leukemia may show higher sensitivities towards tyrosine kinase inhibitors due to a higher addiction to FLT3 gain-of-function signal transduction of leukemia blasts in the relapse setting compared to de novo AML samples [37]. The gene discussed is FLT3; the disease is leukemia.